Secondary pharmacology results indicate that M42.5A (also known as LHY746) is approximately 1/30th of the potency of encorafenib against A375 (BRAF V600E) melanoma cell proliferation when compared with encorafenib and that it shows no significant safety signal in in vitro safety pharmacology testing (data on file). The gene discussed is BRAF; the disease is melanoma.